\n
\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div>
\r\n\r\n
<\/a>\r\n<\/div><\/p>\n<\/div><\/section>
\nOGT establishes commercial partnership with Applied Spectral Imaging<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>

\n
OGT establishes commercial partnership with Applied Spectral Imaging<\/h1>E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nOGT, a Sysmex Group company and leading global provider of clinical research and diagnostic solutions, has formed a new commercial partnership with Applied Spectral Imaging (ASI), a global leader in advanced biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and FISH analysis. The agreement will grant OGT rights to market ASI\u2019s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that combines the strengths of OGT\u2019s CytoCell FISH portfolio with ASI\u2019s imaging and analysis capabilities to deliver operational efficiency in end user\u2019s laboratories.<\/h3>\n<\/p>\n
CytoCell FISH probes from OGT have long been established as best-in-class products for detecting key genetic aberrations for a wide range of sample types. The customisable CytoCell portfolio includes their flagship haematooncology offering, as well as probes to support work in constitutional genetics and solid tumour oncology. The CytoCell range also includes FAST FISH assay solutions, designed for the rapid and accurate detection of the most urgent disorders and earlier this year, eight CytoCell FISH probes were the first to be granted IVDR certification.<\/p>\n<\/div><\/section>
\n
OGT, a Sysmex Group company and leading global provider of clinical research and diagnostic solutions, has formed a new commercial partnership with Applied Spectral Imaging (ASI), a global leader in advanced biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and FISH analysis. The agreement will grant OGT rights to market ASI\u2019s proprietary cytogenetic imaging and analysis solutions in Great Britain, establishing a strategic partnership that combines the strengths of OGT\u2019s CytoCell FISH portfolio with ASI\u2019s imaging and analysis capabilities to deliver operational efficiency in end user\u2019s laboratories.<\/h3>\n<\/p>\n
CytoCell FISH probes from OGT have long been established as best-in-class products for detecting key genetic aberrations for a wide range of sample types. The customisable CytoCell portfolio includes their flagship haematooncology offering, as well as probes to support work in constitutional genetics and solid tumour oncology. The CytoCell range also includes FAST FISH assay solutions, designed for the rapid and accurate detection of the most urgent disorders and earlier this year, eight CytoCell FISH probes were the first to be granted IVDR certification.<\/p>\n<\/div><\/section>
\n
\n